Trevi Therapeutics Targets Major Clinical Milestones for Chronic Cough in 2026
Key Developments: FDA Meeting Set for IPF Program and New RCC Trial Launching
Trevi Therapeutics (NASDAQ: TRVI) is kicking off 2026 with clear strategic priorities: it has secured an End-of-Phase 2 meeting with the FDA for its chronic cough program in idiopathic pulmonary fibrosis (IPF), and it’s preparing to initiate a new Phase 2b trial for refractory chronic cough (RCC) within the first half of the year. These milestones will shape the development trajectory for the company’s lead investigational therapy, Haduvio™ (oral nalbuphine ER), which already boasts statistically significant clinical results in both IPF and RCC patient populations.
Strong Pipeline Progress: Upcoming Regulatory and Clinical Events
Trevi will meet with the FDA in Q1 2026 to discuss the clinical and regulatory roadmap for bringing Haduvio to IPF patients who currently lack approved anti-cough therapies. If all goes as planned, a Phase 3 program in this underserved group will launch soon after. Meanwhile, a Phase 2b trial in RCC patients—another population with no FDA-approved options—will begin in the first half of 2026. Trevi’s management, including new Chief Financial Officer David Hastings, is set to present these updates during the Annual LifeSci Partners Corporate Access Event held alongside the J.P. Morgan Healthcare Conference.
Addressing Significant Unmet Needs in Chronic Cough
Chronic cough remains a major clinical challenge with high unmet needs. Among the estimated 150,000 U.S. IPF patients, roughly two-thirds cope with uncontrolled chronic cough, often coughing up to 1,500 times daily—substantially impacting quality of life and disease progression. Non-IPF interstitial lung disease adds another 228,000 U.S. patients, with over half experiencing persistent cough. RCC, defined as a cough lasting more than eight weeks after other treatable causes have been ruled out, affects 2 to 3 million Americans. Haduvio’s unique dual mechanism—a kappa agonist and mu antagonist—targets the cough reflex through both central and peripheral pathways, differentiating it in an untapped market.
| Patient Population | US Prevalence | % With Chronic Cough | FDA-Approved Therapy Available? |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF) | 150,000 | ~66% | No |
| Non-IPF ILD | 228,000 | 50-60% | No |
| Refractory Chronic Cough (RCC) | 2-3 million | N/A | No |
Will 2026 Be a Pivotal Year for Trevi?
For investors and stakeholders, 2026 is shaping up as a year of focused execution. The upcoming FDA discussions, initiation of a new RCC trial, and preparations for a Phase 3 IPF chronic cough study aim to bring Haduvio closer to regulatory approval and, ultimately, to patients who lack effective therapy options. While risks remain—including the uncertainties of clinical development and regulatory review—Trevi’s progress in a disease area with such significant unmet need could set the stage for substantive value creation, should trials remain positive.
Takeaway: Upcoming Milestones to Watch
The next twelve months will provide crucial answers about Trevi’s ability to execute on its clinical roadmap. For those tracking medical innovation in chronic cough and rare respiratory diseases, monitoring FDA engagement and the early data from the Phase 2b RCC trial will be key. Could Haduvio become the first approved therapy for these conditions? The groundwork being laid in 2026 may set the tone for the years ahead.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI